TY  - JOUR
AU  - Chen, Yen-Yi
AU  - Chang, Pei-Yao
AU  - Wang, Jia-Kang
PY  - 2017
TI  - The use of aflibercept in ophthalmology: a review of randomized controlled trials
JF  - Annals of Eye Science; Vol 2 (March 2017): Annals of Eye Science
Y2  - 2017
KW  - 
N2  - We reviewed randomized controlled trials associated with the intravitreal use of aflibercept for this article. These studies proved that aflibercept is an effective anti-vascular endothelial growth factor agent for the treatment of neovascular age-related macular degeneration (nAMD), myopic choroidal neovascularization (mCNV), diabetic macular edema (DME), and macular edema associated with retinal vein occlusion. The incidence of severe ocular or systemic complications after intravitreal administration of aflibercept was low.
UR  - https://aes.amegroups.org/article/view/3626